BACKGROUND AND OBJECTIVE: Angiotensin-converting enzyme inhibitors (ACEi) are the first selected drugs for hypertensive patients because of its protective properties against heart and kidney diseases. Persistent cough is a common adverse reaction associated with ACEi, which can bind to the treatment cessation, but its etiology remains an unresolved issue. The most accepted mechanism is that the inhibition of ACEi increases kinins levels, resulting in the activation of proinflammatory mechanisms and nitric oxide generation. However, relatively little is known about the genetic susceptibility to ACEi-induced cough in hypertensive patients. METHODS: We carried out a monogenic association analysis of 39 polymorphisms and haplotypes in genes encoding key proteins related to ACEi activity with the occurrence of ACEi-induced cough. We also carried out a digenic association analysis and investigated the existence of epistatic interactions between the analyzed polymorphisms using a logistic regression procedure. Finally, we investigated the predictive value of the identified associations for ACEi-induced cough. RESULTS: We found that genetic polymorphisms in MME [rs2016848, P=0.002, odds ratio (OR)=1.795], BDKRB2 (rs8012552, P=0.012, OR=1.609), PTGER3 (rs11209716, P=0.002, OR=0.565), and ACE (rs4344) genes are associated with ACEi-related cough. For the latter, the effect is sex specific, having a protective effect in males (P=0.027, OR=0.560) and increasing the risk in females (P=0.031, OR=1.847). In addition, genetic interactions between peptidases involved in kinins levels (CPN1 and XPNPEP1) and proteins related to prostaglandin metabolism (PTGIS and PTGIR) strongly modify the risk of ACEi-induced cough presentation (0.102≤OR≤0.384 for protective combinations and 2.732≤OR≤7.216 for risk combinations). CONCLUSION: These results are consistent with the hypothesis that the mechanism of cough is related to the accumulation of bradykinin, substance P, and prostaglandins.
BACKGROUND AND OBJECTIVE: Angiotensin-converting enzyme inhibitors (ACEi) are the first selected drugs for hypertensivepatients because of its protective properties against heart and kidney diseases. Persistent cough is a common adverse reaction associated with ACEi, which can bind to the treatment cessation, but its etiology remains an unresolved issue. The most accepted mechanism is that the inhibition of ACEi increases kinins levels, resulting in the activation of proinflammatory mechanisms and nitric oxide generation. However, relatively little is known about the genetic susceptibility to ACEi-induced cough in hypertensivepatients. METHODS: We carried out a monogenic association analysis of 39 polymorphisms and haplotypes in genes encoding key proteins related to ACEi activity with the occurrence of ACEi-induced cough. We also carried out a digenic association analysis and investigated the existence of epistatic interactions between the analyzed polymorphisms using a logistic regression procedure. Finally, we investigated the predictive value of the identified associations for ACEi-induced cough. RESULTS: We found that genetic polymorphisms in MME [rs2016848, P=0.002, odds ratio (OR)=1.795], BDKRB2 (rs8012552, P=0.012, OR=1.609), PTGER3 (rs11209716, P=0.002, OR=0.565), and ACE (rs4344) genes are associated with ACEi-related cough. For the latter, the effect is sex specific, having a protective effect in males (P=0.027, OR=0.560) and increasing the risk in females (P=0.031, OR=1.847). In addition, genetic interactions between peptidases involved in kinins levels (CPN1 and XPNPEP1) and proteins related to prostaglandin metabolism (PTGIS and PTGIR) strongly modify the risk of ACEi-induced cough presentation (0.102≤OR≤0.384 for protective combinations and 2.732≤OR≤7.216 for risk combinations). CONCLUSION: These results are consistent with the hypothesis that the mechanism of cough is related to the accumulation of bradykinin, substance P, and prostaglandins.
Authors: P S Silva; V Fontana; M R Luizon; R Lacchini; W A Silva; C Biagi; J E Tanus-Santos Journal: Eur J Clin Pharmacol Date: 2012-06-17 Impact factor: 2.953
Authors: Seyed H Mahmoudpour; Abirami Veluchamy; Moneeza K Siddiqui; Folkert W Asselbergs; Patrick C Souverein; Catherine E de Keyser; Albert Hofman; Chim C Lang; Alexander S F Doney; Bruno H Stricker; Anthonius de Boer; Anke H Maitland-van der Zee; Colin N A Palmer Journal: Pharmacogenet Genomics Date: 2017-03 Impact factor: 2.089
Authors: J D Mosley; C M Shaffer; S L Van Driest; P E Weeke; Q S Wells; J H Karnes; D R Velez Edwards; W-Q Wei; P L Teixeira; L Bastarache; D C Crawford; R Li; T A Manolio; E P Bottinger; C A McCarty; J G Linneman; M H Brilliant; J A Pacheco; W Thompson; R L Chisholm; G P Jarvik; D R Crosslin; D S Carrell; E Baldwin; J Ralston; E B Larson; J Grafton; A Scrol; H Jouni; I J Kullo; G Tromp; K M Borthwick; H Kuivaniemi; D J Carey; M D Ritchie; Y Bradford; S S Verma; C G Chute; A Veluchamy; M K Siddiqui; C N A Palmer; A Doney; S H MahmoudPour; A H Maitland-van der Zee; A D Morris; J C Denny; D M Roden Journal: Pharmacogenomics J Date: 2015-07-14 Impact factor: 3.550